2021
Cannabis use disorder among atrial fibrillation admissions, 2008–2018
Chouairi F, Miller PE, Guha A, Clarke J, Reinhardt SW, Ahmad T, Freeman JV, Desai NR, Friedman DJ. Cannabis use disorder among atrial fibrillation admissions, 2008–2018. Pacing And Clinical Electrophysiology 2021, 44: 1934-1938. PMID: 34506639, DOI: 10.1111/pace.14356.Peer-Reviewed Original ResearchConceptsAtrial fibrillation hospitalizationsAF hospitalizationsImpact of CUDNational Inpatient SampleProportion of admissionsDiseases diagnosis codesPrevalence of cannabisHistory of CUDHospital dischargeYounger patientsHigher proportionUnderserved patientsBlack raceDiagnosis codesInpatient SampleInternational ClassificationHospitalizationLegality of cannabisCannabis usePatientsAdmissionCodiagnosisLittle dataCUDCannabisNational Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure
Reinhardt SW, Chouairi F, Miller PE, Clark KAA, Kay B, Fuery M, Guha A, Freeman JV, Ahmad T, Desai NR, Friedman DJ. National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. Journal Of The American Heart Association 2021, 10: e019412. PMID: 34013736, PMCID: PMC8483517, DOI: 10.1161/jaha.120.019412.Peer-Reviewed Original ResearchConceptsReduced ejection fractionComorbid atrial fibrillationHeart failureAtrial fibrillationEjection fractionHospital mortalityHF hospitalizationBackground Heart failureConclusion Atrial fibrillationWhite individualsNational Inpatient SampleMedian hospital chargesMore comorbiditiesComorbid hypertensionHF admissionsHF outcomesPatient demographicsDiabetes mellitusHospital admissionHospital chargesInpatient SampleVascular diseaseHospitalizationPatientsMortality
2019
Digoxin Use and Associated Adverse Events Among Older Adults
Angraal S, Nuti SV, Masoudi FA, Freeman JV, Murugiah K, Shah ND, Desai NR, Ranasinghe I, Wang Y, Krumholz HM. Digoxin Use and Associated Adverse Events Among Older Adults. The American Journal Of Medicine 2019, 132: 1191-1198. PMID: 31077654, DOI: 10.1016/j.amjmed.2019.04.022.Peer-Reviewed Original ResearchConceptsRate of hospitalizationDigoxin useDigoxin toxicityNational Prescription AuditMedicare feeService beneficiariesDigoxin prescriptionAssociated adverse eventsAdverse eventsCohort studyAdverse outcomesSecondary diagnosisNational cohortPrescription auditPrescription trendsClinical guidelinesHospitalizationMortality rateClinical practiceOlder adultsSubsequent outcomesOutcomesToxicityPrescriptionNational-level trends
2014
Digoxin and Risk of Death in Adults With Atrial Fibrillation
Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and Risk of Death in Adults With Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2014, 8: 49-58. PMID: 25414270, PMCID: PMC4334705, DOI: 10.1161/circep.114.002292.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAnti-Arrhythmia AgentsAtrial FibrillationCaliforniaChi-Square DistributionDigoxinFemaleHospitalizationHumansKaplan-Meier EstimateMaleMiddle AgedPatient SelectionPropensity ScoreProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeConceptsRisk of deathIncident atrial fibrillationAtrial fibrillationDigoxin useHigh riskHeart failureIndependent associationPropensity score-matched adultsKaiser Permanente NorthernPrevious heart failureRetrospective cohort studyResearch Network StudySubgroups of ageCohort studyCox regressionAdverse outcomesRisk factorsHospitalizationFibrillationDigoxinDeathLimited dataAdultsRiskHigh rate
2013
Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure
Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6: 525-533. PMID: 24021697, DOI: 10.1161/circoutcomes.111.000079.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCaliforniaCardiotonic AgentsChi-Square DistributionDigoxinDisease ProgressionDrug Therapy, CombinationFemaleGuideline AdherenceHealth Maintenance OrganizationsHeart Failure, SystolicHospitalizationHumansIncidenceMaleMiddle AgedMultivariate AnalysisPractice Guidelines as TopicProportional Hazards ModelsRisk FactorsSex FactorsTime FactorsTreatment OutcomeConceptsIncident systolic heart failureSystolic heart failureSafety of digoxinΒ-blocker useDigoxin useHeart failureHF hospitalizationConcurrent β-blocker useSymptomatic systolic heart failureKaiser Permanente Northern CaliforniaHF disease severityOptimal medical therapyRisk of deathMedical therapyMultivariable analysisContemporary cohortCox regressionClinical guidelinesMedical historyHigh riskHospitalizationHigh mortalityPatientsDisease severityTrial data